Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-11-25

FDA Approved: XOPENEX HFA — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Lupin Pharmaceuticals’ supplemental application for XOPENEX HFA (levalbuterol tartrate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XOPENEX HFA (Levalbuterol tartrate)

Snippet

SUPPL AP for XOPENEX HFA (LEVALBUTEROL TARTRATE)